Feb. 18, 2026
— Jeff Ward, Lehigh Valley News Briefs
Johnson and Johnson, a New Jersey-based pharmaceutical giant, plans to spend $1 billion on a cell-therapy plant in Montgomery County.
The investment is in an expansion of the company’s Janssen Biotech campus near Ambler.
The investment “will support more than 500 skilled biomanufacturing jobs when fully operational and more than 4,000 construction jobs during site development,” according to the J&J statement.
Many pharmaceutical and biotechnology companies operate in the Philadelphia region.
Recently, Eli Lilly announced plans for a $3.5 billion new plant in Lehigh County.
J&J and Lilly are among the world’s largest pharmaceutical companies.
Johnson & John (NYSE:JNJ) has a market capitalization of $587 billion, while Lilly (NYSE:LLY) has a market capitalization of $961 billion.
Here’s a link to the statement from J&J, and below is a cut-and-paste version:
Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania
02/18/2026
- Advanced manufacturing site will utilize cutting‑edge cell therapy technologies to help deliver the company’s portfolio of transformational medicines
- Facility will boost Pennsylvania’s economy by creating more than 4,000 construction jobs and 500 biomanufacturing jobs, while further strengthening the Company’s annual $10 billion economic impact across the state
- Investment is part of Company’s $55 billion U.S. investment by early 2029 and supports plans to manufacture the vast majority of its advanced medicines in the U.S. to meet the needs of patients in the U.S.
NEW BRUNSWICK, N.J.–(BUSINESS WIRE)– Johnson & Johnson (NYSE: JNJ) (the “Company”), healthcare’s leading, most comprehensive innovation powerhouse, today announced a more than $1 billion investment in a next generation cell therapy manufacturing facility in Montgomery County, Pennsylvania. This new facility will further expand the Company’s U.S. manufacturing capacity as it advances its industry leading portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases.
“For 140 years, Johnson & Johnson has been a leading innovator in American healthcare, and we are honored to continue advancing that legacy in Pennsylvania,” said Joaquin Duato, Chairman and Chief Executive Officer of Johnson & Johnson. “By uniting scientific excellence with state-of-the-art manufacturing and strategic investment, and by working collaboratively with our communities, we are delivering for patients and creating significant opportunities for workers and families.”
In building this facility, Johnson & Johnson continues to invest in cutting-edge manufacturing processes and in training to develop a workforce skilled in advanced technologies that are shaping the future of medicine. It will support more than 500 skilled biomanufacturing jobs when fully operational and more than 4,000 construction jobs during site development.
“Pennsylvania is a powerhouse for innovation and manufacturing in the life sciences,” said Governor Josh Shapiro. “Just a few years ago we weren’t even on the field – but today we’re competing and winning. We’ve done it by creating the first economic development plan for Pennsylvania in 2 decades, and following through on it by cutting red tape, making strategic investments in key industries like the life sciences, and strengthening our workforce. That’s why companies like Johnson & Johnson are choosing to double down on their investments here in our Commonwealth – because they know we’ve got the strategy, the workforce, and the speed they need to succeed.”
Decades of Investment in Pennsylvania
This investment further strengthens the Company’s longstanding economic impact across Pennsylvania, which totals approximately $10 billion1 annually. With ten facilities encompassing more than 2 million square feet dedicated to manufacturing, research, distribution, and office operations, Johnson & Johnson maintains one of the most significant, statewide footprints in the healthcare industry.
The announcement is part of the Company’s previously announced $55 billion U.S. investment in manufacturing, research and development, and technology through early 2029.
Lehigh Valley News Briefs 